1 The combined presence of
anti-phospholipid Ab (aPL) and thrombosis is recognized
2 h IgG from patients with PM alone (VT-/PM+),
anti-phospholipid Ab-positive patients without APS, or h
3 fusion of both anti-beta2-glycoprotein I and
anti-phospholipid Ab.
4 e performed experiments to determine whether
anti-phospholipid Abs can also reconstitute I/R injury a
5 We conclude that
anti-phospholipid Abs can bind to tissues subjected to I
6 Because
anti-phospholipid Abs have been shown to mediate fetal g
7 The presence in these mice of
anti-phospholipid Abs reacting with beta2-glycoprotein I
8 an auto-antibodies (B3/33H11, anti-DNA; UK4,
anti-phospholipid)
and six related hybrids have been clo
9 man autoantibodies (B3/33H11, anti-DNA; UK4,
anti-phospholipid)
and six related hybrids have been clo
10 ma levels (P < 0.0001) and low occurrence of
anti-phospholipid antibodies in lupus patients (4.8% ant
11 apoptotic cells are procoagulant and whether
anti-phospholipid antibodies influence this.
12 A subgroup of thrombotic patients with
anti-phospholipid antibodies specifically blocked the ox
13 ospholipid-bound form is the target for most
anti-phospholipid antibodies that are associated with re
14 Anti-phospholipid antibodies that block this process wou
15 ith anti-cardiolipin antibodies, a subset of
anti-phospholipid antibodies, bound to sulfatide-bound b
16 ertain autoantibodies, such as anti-NMDAR or
anti-phospholipid antibodies, promote CNS lupus.
17 systemic lupus erythematosus (SLE) who have
anti-phospholipid antibodies, we addressed whether apopt
18 of these blebs can induce the production of
anti-phospholipid antibodies, which might also enhance t
19 licated in haemostasis and the production of
anti-phospholipid antibodies.
20 sulfatides and thereby becomes a target for
anti-phospholipid antibodies.
21 beta2GPI plasma levels and the occurrence of
anti-phospholipid antibodies.
22 wn, but also sulfatides are targets for most
anti-phospholipid antibodies.
23 s that occur in some lupus patients who have
anti-phospholipid antibodies.
24 ified from the plasma of three patients with
anti-phospholipid antibody syndrome, but not IgG from no
25 bute to some of the clinical symptoms of the
anti-phospholipid antibody syndrome.
26 Anti-phospholipid autoantibodies (aPL) are associated wi
27 Anti-phospholipid mAbs inhibited PBMC HIV-1 infection in
28 We report that four human
anti-phospholipid monoclonal antibodies (mAbs) (PGN632,
29 The combined presence of
anti-phospholipid (
PL) Ab, including lupus anticoagulant
30 romes such as myocardial infarction, sepsis,
anti-phospholipid syndrome and sickle-cell disease.
31 VTE and arterial thrombosis (associated with
anti-phospholipid syndrome) were reported in 0.86% (95%
32 in immune regulation, possibly including the
anti-phospholipid syndrome.
33 target of autoantibodies in humans with the
anti-phospholipid syndrome.
34 uate the risk of thrombosis in patients with
anti-phospholipid syndrome.